Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a …
Full LUCD analysis →
Competitive advantage assessment
Key strengths
Superior Capital ReturnsCapital return quality is top-tier (score 0.99). High ROIC indicates the business is reinvesting at attractive rates.
Lucid Diagnostics Inc. ranks #119 of 160
scored companies in Medical Devices by moat score — the top 74%.
The widest moat in the group is iRadimed Corporation (IRMD)
at 83/100.
Moat scores for companies ranked near LUCD in Medical Devices
How LUCD scores on the Medical Devices & Diagnostics defenses
Pricing Power & Consumable Moat
Score 4
· 25% of the moat score
In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.
R&D Pipeline & Capital Returns
Score 61
· 20% of the moat score
Research spending is how a device company keeps its installed base current, but spending alone proves nothing.
FCF Quality & Cash Conversion
Score 51
· 20% of the moat score
MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.
Commercial Execution
Score 48
· 15% of the moat score
Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.
Capital Structure & Resilience
Score 5
· 12% of the moat score
Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.
Growth Durability
Score 12
· 8% of the moat score
Growth durability separates an expanding installed base from a good product cycle.
Lucid Diagnostics Inc. (LUCD) scores 34 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #119 of 160 scored companies in Medical Devices, the top 74%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is R&D Pipeline & Capital Returns (61/100) and its weakest is Pricing Power & Consumable Moat (4/100).
How does Lucid Diagnostics Inc. compare with other Medical Devices companies?
Lucid Diagnostics Inc. ranks #119 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are AINOS INC C/WTS 29/07/2027 (TO (AIMDW) at 35 just above it and Beyond Air, Inc. (XAIR) at 34 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.
Why is Lucid Diagnostics Inc. scored with the Medical Devices & Diagnostics template?
Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.
Which competitive defenses are measured for Lucid Diagnostics Inc.?
The Medical Devices & Diagnostics template measures 6 defenses, and LUCD scores: Pricing Power & Consumable Moat (4), R&D Pipeline & Capital Returns (61), FCF Quality & Cash Conversion (51), Commercial Execution (48), Capital Structure & Resilience (5), Growth Durability (12). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.